Harish Ramanathan work email
- Valid
- Valid
Harish Ramanathan personal email
- Valid
Harish Ramanathan phone numbers
• Enthusiastic, forward-thinking and detail-oriented biomedical scientist with 18+ years of research experience in the fields of rare genetic diseases, molecular virology, innate immunity and cancer biology. I've been a member of preclinical, translational and exploratory biology team, that successfully took a drug, used in the treatment of anemia in β-thalassemia and myelodysplastic syndromes from bench to bedside. Actively working on two other Acceleron pipelines, Sotatercept, currently in phase 3 clinical trial stage for treatment of group I pulmonary arterial hypertension and in phase I trial for systemic sclerosis with interstitial lung diseases/idiopathic pulmonary fibrosis respectively. • Successfully developed precision-cut lung slices for target-engagement studies, drug-efficacy testing and tissue biomarker development. Experienced in preclinical evaluation of biologics and small molecules in the fields of hematology and fibrosis of lungs and liver. Extensive experience working on mechanism of action studies, target identification and pathway identification using various invitro cell culture and tissue slice models. Successfully developed several cell-based, fluorescent and luminescent enzymatic assays in appropriate platform technologies (such as multicolor FACS, multiplex MSD assays, Luminex, HTRF, ELISA, luminometry) for target-engagement and target identification studies in the fields of TGFb-family of cell signaling pathways, antiviral and anticancer therapeutics. Experience and skills can readily be leveraged for translational research and development of targeted therapeutics. • Experienced in quantitative analytical techniques such as qPCR, quantitative westerns (Odyssey) etc. Well-versed in experiment design, execution, data analysis and can conceive/develop mechanism of haction studies and their application to long-lasting projects. Application of statistical methods for data analyses using Graphpad prism etc. Effective science communicator making complex scientific principles /concepts accessible to audience of diverse backgrounds. Published in major scientific journals. • Excellent team player with good interpersonal and organizational skills and matrix format work culture in demanding environments. Detail-oriented, able to integrate efforts to meet individual goals/deadlines, enable/help team members to achieve collective system-wide goals leading to discovery of novel targets for therapeutic interventions. Career goal is to play a role in a mission that took drugs from bench to bedside.
-
Associate Principal ScientistMerck Mar 2022 - Present -
ScientistAcceleron Pharma Oct 2019 - Mar 2022Cambridge, Ma, UsACCOMPLISHMENTSAnemia: Studied mechanism of action of Luspatercept-mediated erythroid differentiation using in vitro and preclinical β-Thalassemia models. This work is published in J Cell Mol Med (2020). In addition, I studied the role of Luspatercept in α-Thalassemia using preclinical α-Thal mouse models. This work and additional collaborative work with the Luspatercept team in Bristol Meyers Squib, was presented at the ASH-2020 conference. Systemic Sclerosis with Interstitial Lung Disease (SSc-ILD) and Idiopathic Pulmonary Fibrosis (IPF): Initiated and developed precision-cut lung slices as a new tool to monitor progression of lung fibrosis in tissue-culture models, to facilitate target-engagement and efficacy and tissue biomarker analyses alongside other cell-based invitro models. Coordinated various CROs to work on precision-cut lung slices from human Idiopathic pulmonary fibrosis patients to look at efficacy of Acceleron drugs. This work is currently at the manuscript stage for submission in Spring 2022. Pulmonary arterial Hypertension (PAH). Leading in vitro cell-based mechanism of action studies to understand the role of BMPR2 in PAH as well as the role of Sotatercept in altering the signaling pathways that lead to reversal of PAH. Also working with CROs to develop new tools and reagents to probe the MoA studies.NASH-model of liver Fibrosis. Early discovery proof of concept studies using diet-based preclinical models in the development of NASH looking at efficacy of Acceleron drugs in reversing fibrosis. This work is at the POC stage. -
Associate Research ScientistYale University School Of Medicine Aug 2012 - Sep 2019New Haven, Ct, UsAntiviral Discovery: Identified several novel inhibitors of positive-strand RNA viruses. This work is publication in PNAS. Subsequent work is in preparation for publication later this year.Assay Development: Independently developed several mammalian cell-based assays for studying RNA viruses and antiviral discovery.Mechanism of Action Research: Investigated molecular mechanism by which the novel antiviral effectors inhibit RNA virusesManagement, Collaborations, and Communication:• Mentored doctoral and masters students.• Managed and co-led external scientific collaborations.• Managed purchase/planning of laboratory supplies/reagents and financial management of research expenditure. • Communicated science through manuscript writing and presentation in conferences • Successfully collaborated with international scientists in identification of key protease residues within Hepatitis C virus as leads for therapeutic interventions (Published results in 2 articles Plos Pathogens). -
Post-Doctoral Research FellowNih May 2009 - Aug 2012Bethesda, Md, Us• Identified novel function for cellular AAA ATPase p97 as regulator of endocytic vesicle fusion.• Designed and implemented proteomic tools (amine and cysteine-based crosslinking and IP, membrane floatation, density-gradient separation, and mass spectrometry) to demonstrate interaction of p97 with cellular endocytic tether EEA1.• Demonstrated the role of p97 in endocytic trafficking by siRNA-based knockdown strategies and developed assays to monitor trafficking defects of fluorescently labeled endocytic cargos. • Developed cell-free systems to monitor EEA1 ubiquitination using purified proteins (EEA1, ubiquitin-activating and conjugating and E3-ligase enzymes) and ATP-regenerating systems.• Established surface-plasmon resonance (Biacore) experiments to monitor transient protein-protein interactions and determine dissociation constants.• Authored 2 research and 2 review articles (peer-reviewed high-impact articles)• Won prestigious NIH-FARE award (awarded to top 10% of researchers in NIH-wide competition) and Ming K Jeang Award for excellence (picked by the journal editorial committee for that year of publications) -
Post-Doctoral Research FellowNih Jan 2008 - Apr 2009Bethesda, Md, UsValidated structure-function relationship of rotavirus polymerase using in-vitro assays • Employed structure-based site-directed mutagenesis approaches to specifically alter key residues involved in RNA-template recognition, ATP-binding and incoming nucleotide binding.• Cloned and expressed mutagenized polymerase protein variants using baculovirus expression systems and Sf9 insect cells, clonally selected mutant protein clones by plaque purification assay.• Purified recombinant proteins using PEG-cut off and affinity (IMAC) and size-exclusion. Dialyzed and assessed purity by silver-stained gels.• Elucidated key chemistry of rotavirus polymerase. Employed in vitro assays to monitor replication (incorporation of isotope-labeled nucleotides into RNA and running denaturing SDS-PAGE gels).• Revealed mechanisms by which catalytic site residues signal conformational changes on other surfaces of polymerase that ultimately led to shift from RNA-synthesis mode to particle-assembly mode• Authored 2 publications and presented work in scientific meetings• Received National Institutes of Allergy and Infectious Diseases Merit award for unraveling Structure-Function relationship of rotavirus polymerase
-
Graduate Research AssistantUniversity Of Alabama At Birmingham Jun 2003 - Oct 2007Birmingham, Al, UsStudied intracellular trafficking of hantavirus nucleocapsid protein and the intracellular compartment that serve as the initiator of viral RNA synthesis.
Harish Ramanathan Skills
Harish Ramanathan Education Details
-
University Of Alabama At BirminghamMolecular Virology
Frequently Asked Questions about Harish Ramanathan
What company does Harish Ramanathan work for?
Harish Ramanathan works for Merck
What is Harish Ramanathan's role at the current company?
Harish Ramanathan's current role is Associate Principal Scientist, Merck & Co..
What is Harish Ramanathan's email address?
Harish Ramanathan's email address is ha****@****hoo.com
What is Harish Ramanathan's direct phone number?
Harish Ramanathan's direct phone number is +120378*****
What schools did Harish Ramanathan attend?
Harish Ramanathan attended University Of Alabama At Birmingham.
What skills is Harish Ramanathan known for?
Harish Ramanathan has skills like Western Blotting, Molecular Biology, Cell Biology, Protein Chemistry, Biochemistry, Protein Expression, Immunoprecipitation, Immunohistochemistry, Fluorescence Microscopy, Confocal Microscopy, Assay Development, Virology.
Who are Harish Ramanathan's colleagues?
Harish Ramanathan's colleagues are Jeffrey Andersen, Maria Jesus Zeron Gea, Sonia Romero Soto, Km Loma, Excalibvr Merlin, Gary Zelko, Monique Harnie-Cousseau.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial